阿斯利康的T790M牛逼新药AZD9291的1期临床结果出来了

9291比4002的优点分别在哪？期望专家总结一下。

期待新药

南宁阿梁 发表于 2013-12-2 12:54

                               
登录/注册后可看大图

有点看不明白，AZD9291单独那条红线是不是说一线上AZD9291可以把19突变的癌细胞灭杀到只剩千分之一？

这个我也有点疑问，一般的异种移植物体内肿瘤模型都是标明了使用肿瘤体积（tumor vol）作纵坐标的，并且也不是对数比例尺，我再找找有没有更详细一点的动物实验数据资料

老马 发表于 2013-11-15 11:20

                               
登录/注册后可看大图

AZD9291 and 2 active metabolites (AZ5104 and AZ7550)

当研究人员分析实验小鼠的血液样本时，他们发现了AZD9291的降解产物：AZ5104，与AZD9291一同在血液里循环流动。接着，他们发现AZ5104同样是激活型和抗性突变型EGFR的有效抑制剂，于是他们推测AZ5104和AZD9291都具有抗癌活性。        根据来自小鼠的血样分析结果，研究人员制作了一个数学模型，用以评估AZD9291向AZ5104转变的动力学变化，并计算最终的肿瘤抑制效率。这一实验有助于帮他们为同时患有激活型和抗性突变型EGFR的NSCLC患者选择最合适的AZD9291使用计量。

期待，不知道有没有人拿到YL药，希望能尽快普及，几位强了，一直在钻研新药，赞。
继续学习。。

http://www.inspire.com/groups/lu ... one-on-trial-t790m/
My husband was treated with Tarceva ( erlotinib ) an EGFR inhibitor drug following diagnosed with Advanced stage Iv NSC Lung cancer for nearly 15 months after non responding to several courses of double agents chemotherapy. Unfortunately he developed resistant mutation and tarceva was no longer effective resulting in tumour progression and several metastatic lymph nodes enlargement . He was offered to participate in Phase I trial of AZD9291 drug developed by Astra Zenica. He is one of new participant on very dose AZD9291 ( 160 mg ) daily for the past 7-8 weeks his recent CT scan on 21/10/2013 has been promising. He had intractable diarrhoea & abdominal cramps associated with extreme tiredness & some weight loss with such high dose. He is now taking reduced dose 80 mg daily since 28/10/13 feel much better although still suffers from loose motions. He feels more settled and positive with AZD 9291 treatment so far. The results from other European trial centres has been encouraging showing 58 percent response even at lower dose. He feels it is worthwhile treatment with mild/moderate side effects.

DougGuitarPlayer :
My wife was treated with Tarceva since being diagnosed with Stage IV NSCLC on March 29th, 2013. As of today, the tumors are again growing and therefore becoming resistant to the Tarceva. Her doctor at Dana Farber recommends getting into the trial for AZD 9291, however, we were told that the trial at Dana Farber is currently closed, and may reopen in January 2014. It is not clear whether you will need to demonstrate a T790M mutation to be accepted into the trial. By the way, the recommended plan C was chemo and continue Tarceva for a period.

There was also some discussion whether getting into a Clovis trial would be a better option, but that is not offered at Dana Farber.

Given that we have few options we are hoping to hear some positive stories from the trials of AZD 9291.
===================================================================
Diceros ：
We live in the UK where AZD9291 is on clinical trial. My wife has been taking it for about six months. It has reduced her tumour by about two-thirds so far. The side effects have been minimal. The hope of course is that this drug will not only shrink the tumour but stop it regrowing and spreading.

老马 发表于 2013-12-7 01:14

                               
登录/注册后可看大图

DougGuitarPlayer :
My wife was treated with Tarceva since being diagnosed with Stage IV NSCLC on Ma ...

谢谢老马的辛苦,论坛有个翻译就好了,我大概看到这药效果很好啊,,

AZD9291患者第一次剂量递增研究
http://clinicaltrials.gov/show/NCT01802632
药物： AZD9291
起始剂量为20毫克，每日服用一次。如果容忍的同伙随后将测试增加剂量AZD9291的，直到最大耐受剂量或最大剂量是可行的定义


D.罗斯Camidge ，医学博士，主任，胸部肿瘤学临床课程，科罗拉多大学癌症中心，讨论我的研究看AZD9291治疗非小细胞肺癌的一个阶段。

AZD9291是表皮生长因子受体（EGFR ）激活和耐药突变的不可逆抑制剂，似乎被很好的耐受性试验。 Camidge说，他觉得很有趣，有些患者并有皮疹的一点点，这可能表明，研究人员已经接近理想的剂量。 AZD9291展示关于整体和大约56 ％的回应率在T790M突变阳性患者46％的回应率。

眼下， Camidge说， AZD9291可能是一个“改变游戏规则”，并预计快速通道审批。撤消修改

学习得很吃力，我是英盲